(10) Reportable Segments and Major Concentration Data Our reportable segments are Diagnostics and Life Science. The Diagnostics segment consists of: (i) manufacturing operations for infectious disease products in Cincinnati, Ohio; Quebec City, Canada; and Modiin, Israel; (ii) manufacturing operations for blood chemistry products in Billerica, Massachusetts (near Boston); and (iii) the sale and distribution of diagnostics products domestically and abroad. The Life Science segment consists of: (i) manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; and Luckenwalde, Germany; and (ii) the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents domestically and abroad, including a sales and business development facility, with outsourced distribution capabilities, in Beijing, China to pursue revenue opportunities in Asia. Two Diagnostics customers accounted for 10% and 11%, respectively, of consolidated net revenues in fiscal 2018, with no individual customers from either reportable segment accounting for 10% or more of consolidated net revenues in either fiscal 2020 or fiscal 2019. However, during fiscal 2020, reportable segment revenues were concentrated as follows: Diagnostics Segment Two diagnostics distributors: 23% of segment revenues; 12% of consolidated revenues Life Science Segment Three diagnostic manufacturers: 27% of segment revenues; 14% of consolidated revenues Accounts receivable from one of the Diagnostics customers accounted for 11% of consolidated accounts receivable at September 30, 2019, while one of the Life Science customers accounted for 15% of consolidated accounts receivable at September 30, 2020. Revenue generated by the Company outside of the U.S. and its territories totaled approximately $121,596, $74,193 and $71,494 in fiscal 2020, 2019 and 2018, respectively, and our three major product families  gastrointestinal, respiratory illnesses and blood chemistry  accounted for 39%, 57% and 59% of consolidated net revenues in fiscal 2020, 2019 and 2018, respectively. In addition, products related to COVID-19 accounted for approximately 28% of consolidated fiscal 2020 revenues. We currently purchase on a sole-source basis from a U.S. manufacturer the instruments on which our Alethia molecular testing platform operates, and from an Australian manufacturer the instruments on which our Curian testing platform operates. Significant revenue information by country for the Diagnostics and Life Science segments is as follows. Revenues are attributed to the geographic area based on the location to which the product is delivered. Year Ended September 30, 2020 2019 2018 United States and territories $ 95,382 $ 107,890 $ 121,609 Italy 9,797 10,911 10,398 United Kingdom 2,312 2,396 2,340 France 2,238 2,446 2,353 Belgium 1,440 1,468 1,711 Holland 1,183 1,413 1,454 Japan 848 1,572 1,307 Other countries 7,932 8,586 9,282 Total Diagnostics $ 121,132 $ 136,682 $ 150,454 Year Ended September 30, 2020 2019 2018 United States and territories $ 36,689 $ 18,931 $ 20,468 China 19,047 8,464 8,347 United Kingdom 14,765 4,709 5,201 Germany 14,190 12,663 8,108 Spain 7,242 4,414 4,187 Australia 5,957 3,458 3,631 France 5,579 2,200 2,040 Italy 4,067 1,357 971 Japan 3,707 1,624 1,932 Holland 3,212 710 715 Indonesia 3,027 169 162 Turkey 2,819 290 188 Finland 2,518 500 467 India 2,099 143 251 South Korea 1,908 1,134 2,044 Other countries 5,709 3,566 4,405 Total Life Science $ 132,535 $ 64,332 $ 63,117 In locations outside the U.S., the Companys identifiable assets were concentrated as follows at the end of the most recent fiscal years, with no additional countrys total of assets exceeding $5,000: As of September 30, 2020 2019 Israel $ 70,097 $  United Kingdom 27,373 22,963 Germany 12,877 7,141 Canada 9,865 6,807 Italy 7,858 7,557 Segment information for the interim periods is as follows : Diagnostics Life Science Corporate(1) Eliminations(2) Total Fiscal 2020 Net revenues - Third-party $ 121,132 $ 132,535 $  $  $ 253,667 Inter-segment 326 261  (587 )  Operating income 3,885 68,826 (11,437 ) 50 61,324 Depreciation and amortization 11,451 2,116   13,567 Capital expenditures 1,850 1,449   3,299 Goodwill 94,855 19,331   114,186 Other intangible assets, net 83,179 18   83,197 Total assets 306,812 98,483  (34 ) 405,261 Fiscal 2019 Net revenues - Third-party $ 136,682 $ 64,332 $  $  $ 201,014 Inter-segment 462 361  (823 )  Operating income 25,390 17,581 (10,373 ) 101 32,699 Depreciation and amortization 7,676 2,288   9,964 Capital expenditures 2,049 1,748   3,797 Goodwill 70,395 18,846   89,241 Other intangible assets, net 59,807 436   60,243 Total assets 255,169 70,392  (83 ) 325,478 Fiscal 2018 Net revenues - Third-party $ 150,454 $ 63,117 $  $  $ 213,571 Inter-segment 392 397  (789 )  Operating income 34,603 11,765 (15,076 ) 292 31,584 Depreciation and amortization 6,557 2,131   8,688 Capital expenditures 2,477 1,724   4,201 Goodwill 35,213 19,424   54,637 Other intangible assets, net 22,068 1,045   23,113 Total assets 180,978 70,341  58 251,377 (1) Includes Restructuring and Selected Legal Costs of $2,080, $2,596 and $7,779 in fiscal years 2020, 2019 and 2018, respectively. (2) Eliminations consist of inter-segment transactions. A reconciliation of segment operating income to consolidated earnings before income taxes for the years ended September 30, 2020, 2019 and 2018 is as follows: Year Ended September 30, 2020 2019 2018 Segment operating income $ 72,761 $ 43,072 $ 46,660 Corporate expenses (11,437 ) (10,373 ) (15,076 ) Interest income 142 681 418 Interest expense (2,632 ) (1,945 ) (1,520 ) Other, net 459 122 (102 ) Consolidated earnings before income taxes $ 59,293 $ 31,557 $ 30,380 Transactions between segments are accounted for at established intercompany prices for internal and management purposes with all intercompany amounts eliminated in consolidation.